Eli Lilly Completes $9.0 Billion Debt Offering, Funds Centessa Acquisition

summarizeSummary

Eli Lilly completed a $9.0 billion debt offering, raising approximately $8.94 billion in net proceeds, with a significant portion explicitly tied to financing the previously announced Centessa acquisition.

check_boxKey Events

• Completed $9.0 Billion Debt Offering

  Eli Lilly completed an offering of various Floating Rate Notes and Fixed Rate Notes totaling $9.0 billion in aggregate principal amount.

• Raised $8.94 Billion in Net Proceeds

  The company received approximately $8.94 billion in net proceeds from the debt offering, after deducting underwriting discounts.

• Financing Linked to Centessa Acquisition

  A significant portion of the notes ($6.25 billion) are subject to a special mandatory redemption if the Centessa Acquisition is not consummated by March 31, 2027, explicitly linking the financing to the previously announced $6.3 billion acquisition.

• Diverse Note Maturities and Rates

  The offering includes both floating and fixed-rate notes with maturities ranging from 2028 to 2066, diversifying the company's debt profile.

auto_awesomeAnalysis

Eli Lilly has successfully completed a substantial debt offering, raising approximately $8.94 billion in net proceeds. This capital raise is significant for funding the company's strategic growth initiatives. A key detail is the special mandatory redemption clause for $6.25 billion of the notes, explicitly linking this financing to the previously announced Centessa acquisition. This demonstrates the company's commitment to its M&A strategy and provides the necessary capital to execute it, following a period of strong operational performance and product development.